Targeting T-cell cancers with engineered immune cells
Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies
This study is testing a new kind of immune cell therapy that aims to help people with tough-to-treat blood cancers like T-cell leukemia and lymphoma by using specially modified cells to attack cancer while protecting healthy cells.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | March Biosciences INC NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11006944 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of immune cell therapy called dual-specific CAR-T cells to treat aggressive T-cell malignancies like T-cell acute lymphoblastic leukemia and T-cell lymphoma. The approach involves using donor-derived T-cells that are modified to target specific markers found on cancer cells while avoiding damage to healthy cells. By engineering these cells to resist self-targeting and minimizing the risk of complications, the goal is to improve treatment outcomes for patients with limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma.
Not a fit: Patients with B-cell malignancies or those who do not have T-cell cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with T-cell malignancies.
How similar studies have performed: Previous research has shown promise with CAR-T cell therapies in B-cell cancers, but this approach for T-cell malignancies is novel and aims to address specific challenges faced in those cases.
Where this research is happening
Houston, United States
- March Biosciences INC — Houston, United States (Active)
Researchers
- Principal investigator: Hein, Sarah Marie — March Biosciences INC
- Study coordinator: Hein, Sarah Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.